drugset

drugset / Trial / NCT04986176

HC-1119 Adjuvant Treatment for Hospitalized COVID-19 Patients

NCT04986176 ↗

Phase 3 Unknown 602 enrolled Applied Biology, Inc. Hinova Pharmaceuticals Inc. · collab

RandomizedParallel-groupTriple-blindTreatment

Summary

The primary purpose of this study is to evaluate the efficacy of HC-1119 as an adjuvant treatment for hospitalized COVID-19 male and female patients.

Timeline

Start: 2022-04-15
Primary completion: 2022-12-31
Completion: 2022-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HC-1119	Unknown	160 mg	Oral

Indications